Patents by Inventor Klaus Dinkel

Klaus Dinkel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cyclosporin derivatives
    Patent number: 9453051
    Abstract: The present invention relates to novel cyclosporin derivatives that do not cross the cellular membrane. The compounds according to the invention are used in medicine, more particularly in the treatment/diagnosis of acute and chronic inflammatory diseases, viral infections, cancer, degenerative muscle diseases, neurodegenerative diseases and damage that is associated with calcium homeostasis impairment. The novel cyclosporin derivatives additionally have no immunosuppressive effect.
    Type: Grant
    Filed: August 29, 2012
    Date of Patent: September 27, 2016
    Assignees: Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V., Lead Discovery Center GmbH
    Inventors: Gunter Fischer, Miroslav Malesevic, Frank Erdmann, Jan Kuhling, Michael Bukrinsky, Stephanie Constant, Gerd Ruhter, Peter Nussbaumer, Klaus Dinkel
  • CYCLOSPORIN DERIVATIVES
    Publication number: 20140316104
    Abstract: The present invention relates to novel cyclosporin derivatives that do not cross the cellular membrane. The compounds according to the invention are used in medicine, more particularly in the treatment/diagnosis of acute and chronic inflammatory diseases, viral infections, cancer, degenerative muscle diseases, neurodegenerative diseases and damage that is associated with calcium homeostasis impairment. The novel cyclosporin derivatives additionally have no immunosuppressive effect.
    Type: Application
    Filed: August 29, 2012
    Publication date: October 23, 2014
    Applicants: LEAD DISCOVER CENTER GMBH, MAX-PLANCK-GUSELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V.
    Inventors: Gunter Fischer, Miroslav Malesevic, Frank Erdmann, Jan Kuhling, Michael Bukrinsky, Stephanie Constant, Gerd Ruhter, Peter Nussbaumer, Klaus Dinkel
  • Trojan horse immunotherapy
    Publication number: 20080038237
    Abstract: The present invention provides methods for the delivery of therapeutic proteins to an area of inflammation and neuronal damage within the central nervous system (CNS). In this invention, immunocytes that can cross the blood brain barrier and access sites of CNS injury/inflammation, are genetically engineered to express and secrete a therapeutic protein of interest and are transplanted into a subject having a CNS injury. These genetically modified “carrier immunocytes” home to the site of a CNS lesion and secret the therapeutic agent, thereby ameliorating disease symptoms and pathology.
    Type: Application
    Filed: February 28, 2007
    Publication date: February 14, 2008
    Inventors: Robert Sapolsky, Nathan Manley, Sheila Brooke, Klaus Dinkel, Carolina Munhoz, Angela Riepel, Andrea Nicholas